Ritter Pharmaceuticals: RP-G28 and Lactose Intolerance [transcript] [audio]

Guest: Andrew Ritter

Presenter: Neal Howard

Guest Bio: Mr. Ritter co-founded Ritter Pharmaceuticals, Inc., upon his own personal affliction with lactose intolerance. He spearheaded the development of the company’s lead compound, RP-G28, which has the potential to become the first FDA-approved treatment for lactose intolerance. The therapeutic is currently in Phase 3 clinical trials. The company was originally launched out of Ritter Naturals Sciences, a direct-to-consumer healthcare marketing company, founded by Mr. Ritter in 2004, which developed and commercialized digestive healthcare products: Lactagen®, Health Essentials™ and Better Digestion™. Mr. Ritter holds over a dozen patents with over twenty additional patents pending in the United States and other key international markets. In addition, Mr. Ritter has co-published articles in the Proceedings of the National Academy of Sciences, Nutrition Journal, Food Technology, among others.

Segment Overview: Andrew Ritter, co-founder and president of Ritter Pharmaceuticals discusses the company history and the recent report on the RP-G28 phase 2b study that shows data that promotes beneficial adaptation of the gut microbiome. He also talks about the difficulties of living with moderate to severe lactose intolerance, and the significance of a potential FDA-approved treatment.


Leave a Reply

You must be logged in to post a comment.